和田割包皮长环切手术的费用和田包皮过长切割费用,和田早孕试纸晚多久测出,和田治疗包茎手术费用,和田包皮一般多少钱,和田女性专科哪个好,和田男子包皮手术疼不疼,和田做一次包茎切除要多少钱

ISLAMABAD, Nov. 14 (Xinhua) -- Pakistan ranks the seventh in the world in terms of diabetes prevalence rate and over 7.1 million people in the country are diabetes patients, reported local media on Monday.Quoting a report by the World International Diabetes Federation, a local English newspaper "The News" said that every year 89,000 people die of diabetes in Pakistan and the number of diabetes patients in the country could hit 11.5 million by the year 2025 if proper measures were not taken.This would make Pakistan the world's fifth largest country in terms of its number of diabetes patients 14 years later, warned the report.At a seminar organized Monday in Islamabad to observe the World Diabetes Day which falls on Nov. 14, Dr. Abdus Salam from Shifa International Hospital, a private-run hospital in the capital city, said that every ten seconds, two people are diagnosed with diabetes and one person dies of diabetes-related causes.The average age of diabetes patients in Pakistan is one of the lowest in the world, said the report. In a bid to raise public awareness about the harmful effects of diabetes, various diabetes camps, scientific sessions, seminars and walks were organized across the country on Monday to mark the World Diabetes Day.In a message delivered on Sunday, Pakistani Prime Minister Yusuf Raza Gilani said that the World Diabetes Day draws attention to the lethality of the disease and underscores the need of preventive measures at individual and collective levels."Diabetes is a killer which is taking the life of one person out of every 800," said the prime minister, adding that "this disease hits people of all age groups, rich and poor alike without any discrimination."

BEIJING, Jan. 10 (Xinhua) -- Chinese State Councilor Dai Bingguo on Tuesday attended a reception at the Great Hall of People in Beijing celebrating the 20th anniversary of the establishment of diplomatic ties between China and five Central Asian countries.China successively established diplomatic relations with Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan and Turkmenistan in early January of 1992.In his address, Dai said relations between China and the five nations have achieved comprehensive and significant progress since they forged diplomatic ties 20 years ago, featuring frequent high-level visits, deepened political mutual trust, mutual support on major issues of each other's concern and expanded mutually beneficial cooperation in various fields.China and the five countries have maintained close coordination within the framework of the United Nations and the Shanghai Cooperation Organization and have positively contributed to safeguarding and promoting the world's peace, stability and development, he said.Noting China and the Central Asian nations are good neighbors, good friends and good partners, Dai said, no matter how the international situation changes, China will adhere to the policy of building friendship and partnership with its neighbors and support the five nations to independently choose their development path.China will unswervingly advance traditional friendship and cooperation with the five nations and will work with them to make unremitting efforts for building a harmonious world of lasting peace and common prosperity, he said.Dai said China will take the opportunity of celebrating the 20th anniversary to increase political mutual trust, expand mutually beneficial cooperation and develop traditional friendship with the five nations, in the hope of jointly creating a bright future for their relations.Li Xiaolin, president of the Chinese People's Association for Friendship with Foreign Countries, and diplomatic envoys from the five Central Asian nations also addressed the reception.

BEIJING, Dec. 30 (Xinhua) -- China will push to properly resolve the case of a Chinese skipper indicted by Japan, the Foreign Ministry said Friday.Spokesman Hong Lei said this is a common fishing case, and the Chinese embassy in Japan has dispatched officials to visit the skipper.China requests that Japan ensure the rights of the Chinese skipper, Hong said, and China is communicating closely with Japan in order to properly resolve the case.The Chinese government has been requiring fishermen to fish legally, Hong said, adding that the competent authorities have done a lot in this area, and he promised to promote the management and education of Chinese fishermen.Japanese prosecutors have indicted the captain of a Chinese fishing boat for illegally operating in Japanese waters, a local official said Friday.The Nagasaki District Public Prosecutors Office has finalized its case against Zhong Jinyin, 39, following his December 20 arrest near islands off southwest Japan, according to the official.The prosecutors have not indicated whether the skipper has admitted to the charge.

BEIJING, Oct. 18 (Xinhuanet) -- Some seaweeds can kill the reef-building corals around them by emitting anti-coral chemicals, a new study found.The study was published Monday in the online edition of the journal Proceedings of the U.S. National Academy of Sciences (PNAS).The researchers investigated the interactions between eight different species of seaweed and three species of coral growing in the waters nearby the Fiji Islands, and identified a class of anti-coral organic compounds known as terpenes.These chemicals, found on the surfaces of several species of seaweed, can kill the coral by suppressing its photosynthesis.The finding suggests that the living space competition with seaweeds could be a factor of the coral's worldwide decline.Plant-eating fish normally controls seaweed growth on coral reefs, but the populations of these consumers are declining by the overfishing, which eventually resulted in the seaweed's dominant position, according to the researchers.Despite overfishing, pollution and warming oceans are also the contributors to coral's worldwide decline, said Jennifer Smith, a marine ecologist at the University of California, San Diego.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.